Suicide and Self-Harm Events With GLP-1 Receptor Agonists
This systematic review and meta-analysis evaluates the risk of suicidality and self-harm in randomized, placebo-controlled trials of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in adults with diabetes or obesity.
Lilly’s oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity
In ATTAIN-2, orforglipron met the primary and all key secondary endpoints, with compelling efficacy results and a safety profile consistent with injectable GLP-1 medicines
Oral GLP-1 Pill For Weight Loss Shows Promise, But Challenges Remain
Experts see a place for pill formulations of GLP-1s as treatment for patients to switch to after reaching a target weight or blood sugar level on injectable versions.
HIMS’ Personalized Wellness Platform Expands Preventive Care Access
The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, positions itself as a consumer-first health and wellness platform, designed to transform the way individuals access and manage their care. Launched in 2017, the company has built a digital ecosystem that connects patients to licensed healthcare professionals, enabling treatment for a broad range […]
Weight loss drugs protect heart patients, study suggests
Health Weight loss drugs protect heart patients, study suggests 40% lower risk of hospitalization or death Mass General Brigham Communications September 2, 2025 3 min read High-risk patients with heart failure had an over 40 percent lower risk of hospitalization or death after initiating weight loss drugs semaglutide or tirzepatide compared to placebo by proxy, […]
GLP-1s reduce heart failure death, hospitalization: 3 things to know
Both semaglutide and tirzepatide were shown to “significantly reduce” the risk of hospitalization and all-cause mortality for heart failure patients, according to a study published Aug. 31 in JAMA. Researchers from Somerville, Mass.-based Mass General Brigham analyzed U.S. insurance claim data to emulate two previous semaglutide and tirzepatide trials at a larger scale, an Aug. […]
GLP-1 Receptor Agonists Linked to Reduced Risk for Developing Uveitis
TUESDAY, Sept. 2, 2025 — Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a reduction in the risk for developing uveitis, according to a study published online Aug. 28 in JAMA Ophthalmology.Nitesh Mohan, from the Cole Eye…
GLP-1 Drugs May Cut Dementia and Stroke Risk for Some Patients
For patients with type 2 diabetes (T2D) and obesity, glucagon-like peptide-1 (GLP-1) drugs may offer neuroprotective and cerebrovascular benefits in addition to glycemic control, a recent study found.
I Am Taking a GLP-1 Weight-Loss Medication—What Should I Know?
This JAMA Internal Medicine Patient Page describes how glucagon-like peptide-1 (GLP-1) receptor agonists work and what behaviors to adopt while using them.
A GLP-1 Pill Is Coming to Shake Up the Weight Loss Drug Market
Eli Lilly is on track to release orforglipron next year, which has showed an average of 12 percent weight loss.